Published : 03/12/2024  -  Categories : News

Understanding the challenges of antifungal agents, Alsachim has applied its know-how to provide the first labeled internal standard of Amphotericin B on the market. Indeed, this antifungal medication wich is used for the treatment of invasive fungal infections, need to be monitor due to its potential side effects. The SIL standard enables quantitative accurate analysis of Amphotericin B by LC-MS/MS.

Amphotericin B, a broad-spectrum antifungal

Amphotericin B, a polyene antifungal medication derived from Streptomyces nodosus, holds significance in the treatment of various fungal infections. This broad-spectrum antifungal agent acts by binding to ergosterol in fungal cell membranes, disrupting membrane integrity and leading to fungal cell death.

Primarily employed in the treatment of systemic fungal infections, especially in immunocompromised patients, Amphotericin B addresses conditions such as invasive candidiasis, aspergillosis, and cryptococcal meningitis. Notably, its use becomes paramount when other antifungal agents may be less effective or resistance is encountered. This antifungal is effective against a range of pathogenic fungi, making it a crucial therapeutic tool.

While routine monitoring of Amphotericin B levels in the blood is not common, close attention is given to potential side effects. Regular assessments of renal function, through measures such as serum creatinine and blood urea nitrogen, are essential due to the drug's association with nephrotoxicity. Monitoring of electrolyte levels, particularly potassium and magnesium, is also part of the clinical management to address potential imbalances.

From the R&D to the SIL internal standard for Amphotericin B monitoring

Despite of its potential serious side-effetcs, Amphotericin B remains a critical antifungal medication offering valuable treatment options for severe fungal infections. Its broad spectrum of action makes it one of the most widely used in the treatment of potentially life-threatening cases.

Healthcare providers tailor monitoring strategies based on individual patient factors to ensure the optimal balance between therapeutic efficacy and safety.

At Alsachim, our willingness to contribute to the progress of Science and Research drives us to constantly develop new products. By this commitment, our experienced teams of chemists carried out an extensive R&D work and have synthesized the first stable isotope-labeled analog of Amphotericin B : [13C6]-Amphotericin B.

This SIL internal standard provides accurate quantification of Amphotericin B for your LC-MS studies.

Discover more information of [13C6]-Amphotericin B

stable isotope labeled internal standard of Amphotericin B